盐酸多柔比星联合环磷酰胺治疗乳腺癌患者的临床疗效及对血清因子水平的影响

Efficacy of hydrochloric acid domorbicin combined with cyclophosphamide for breast cancer and its effect serum factor levels

目的探讨盐酸多柔比星联合环磷酰胺治疗乳腺癌患者的临床疗效及对血清因子水平的影响。方法选取2015年6月至2017年6月间新疆医科大学附属肿瘤医院收治的60例乳腺癌患者,采用随机数字表法分为观察组和对照组,每组30例。对照组患者采用多西他赛和环磷酰胺治疗,观察组患者采用盐酸多柔比星联合环磷酰胺治疗,对两组患者治疗前后的血清因子水平、氧化应激标志物水平及临床疗效进行比较。结果治疗前,两组患者各项血清因子水平和氧化应激标志物水平比较,差异均无统计学意义。治疗后,两组患者血清白介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)和干扰素y(IFN-y)水平均较治疗前增高,白介素-6(IL-6)水平均降低,且观察组患者IL-2、TNF-α和IFN-y水平与对照组比较,差异均有统计学意义(均P<0.05)。治疗后,观察组患者丙二醛(MDA)、超氧化物歧化酶(SOD)及谷胱甘肽过氧化物酶(GSH-Px)氧化应激标志物水平与对照组比较,差异均有统计学意义(均P<0.05)。观察组患者临床有效率为90.0%,高于对照组的83.3%,但两组比较,差异无统计学意义(P>0.05)。结论盐酸多柔比星联合环磷酰胺治疗乳腺癌患者有效,对细胞免疫功能有改善作用,降低机体氧化应激,值得推广应用。

Objective To explore the efficacy of hydrochloric acid domorbicin combined with cyclophosphamide for breast cancer and its effect serum factor levels. Methods Between June 2015 and June 2017,60 patients with breast cancer treated at Affiliated Cancer Hospital of Xinjiang Medical University were selected. Using a random number table,the patients were divided in an observation group and a control group with 30 patients in each group. The observation group was given hydrochloric acid domorbicin combined with cyclophosphamide and the control group was given docetaxel combined with cyclophosphamide. The serum level factors,oxidative stress markers and clinical therapeutic efficacy were compared between the two groups. Results There was no significant difference in serum level factors and oxidative stress markers between the two groups before the treatment. After the treatment,interleukin-2（ IL-2）,tumor necrosis factor（ TNF-α） and interferon-y（ IFN） increased and IL-6 decreased in both groups. There is statistical significance difference in IL-2,TNF-α and IFN-y between the two groups（ P〈0. 05）. After treatment,there was statistical significance difference in malondialdehyde（ MOD）,superoxide dismutase（ SOD） and glutathione peroxidase（ GSH-Px） markers of oxidative stress levels between the two groups（ P〈0. 05）. The treatment efficacy was 90. 0% for the observation group which was higher 83. 3% of the control group,but the difference between the two groups was not statistically significant（ P〉0. 05）.Conclusion Hydrochloric acid domorbicin combined with cyclophosphamide shows high efficacy for breast cancer. It can improve the immune function of cellular and decrease the effect of the oxidative stress and deserve the clinical expansion.